Rogers Corp【ROG】株式ニュース

Rogers Corporation Reports First Quarter 2026 ResultsApril 28, 2026 4:05 PM
Business Wire

Net sales of $200.5 million increased 5.2% year-over-year (YoY)

Gross margin of 32.2% increased 230 basis points YoY

Net income of $4.5 million increased by $5.9 million YoY

Adjusted EBITDA of $32.0 million increased by $12.5 million YoY

Diluted earnings per share of $0.25 increased by $0.33 YoY

Adjusted earnings per share of $0.75 increased by $0.48 YoY

Rogers Corporation (NYSE:ROG) today announced financial results for the first quarter of 2026.

"Our consistent execution continued in the first quarter with results that met or exceeded the mid-point of guidance across all financial metrics,” stated Ali El-Haj, Rogers' Interim President and CEO. "We also achieved meaningful improvement in profitability with adjusted earnings per share more than doubling and adjusted EBITDA margin expanding by 580 basis points year over year.”

"The first quarter results together with our stronger second quarter guidance, demonstrates the progress of our commercial and profitability improvement initiatives, which continue to gain momentum. With key products in development that address needs in growing markets, and a strong balance sheet that provides strategic flexibility, we are well positioned to capitalize on compelling market opportunities ahead."

Financial Overview

GAAP Results (dollars in millions, except per share amounts)

Q1 2026

Q4 2025

Q1 2025

Net Sales

$200.5

$201.5

$190.5

Gross Margin

32.2%

31.5%

29.9%

Net Income (Loss)

$4.5

$4.6

$(1.4)

Diluted Earnings (Loss) Per Share

$0.25

$0.26

$(0.08)

Adjusted Earnings Per Diluted Share1

$0.75

$0.89

$0.27

Adjusted EBITDA1

$32.0

$34.4

$19.5

Net Cash Provided by Operating Activities

$5.8

$46.9

$11.7

Free Cash Flow1

$1.1

$42.2

$2.1

1 - Adjusted Earnings Per Diluted Share, Adjusted EBITDA and Free Cash Flow are non-GAAP measures. A reconciliation of non-GAAP to GAAP measures is provided in the schedules included below.

Q1 2026 Summary of Results

Net sales of $200.5 million increased 5.2%, or $10.0 million, versus the first quarter of 2025, inclusive of a $7.9 million foreign currency benefit due to the appreciation of the euro and Chinese yuan relative to the U.S. dollar. By end market, industrial, and electronics and communications sales increased, while automotive sales declined.

GAAP earnings per diluted share were $0.25 compared to a loss per share of $(0.08) in Q1 2025. On an adjusted basis, earnings were $0.75 per diluted share compared to earnings of $0.27 per diluted share in the prior year quarter. There was minimal foreign currency benefit to adjusted earnings per share. The improvement in adjusted earnings resulted from higher sales, improvements in gross margin and lower operating expenses.

First quarter ending cash and cash equivalents were $195.8 million, a decrease of $1.2 million compared to the prior quarter. Net cash provided by operating activities was $5.8 million and capital expenditures were $4.7 million.

Financial Outlook

(dollars in millions, except per share amounts)

Q2 2026

Net Sales

$210 to $220

Gross Margin

32.5% to 33.5%

Adjusted Earnings Per Diluted Share

$0.90 to $1.10

Adjusted EBITDA

$35 to $41

2026

Capital Expenditures

$30 to $40

Conference Call and Additional Information

A conference call to discuss the results for the first quarter will take place today, Tuesday, April 28, 2026 at 5:00 pm ET. A live webcast of the event and the accompanying presentation can be accessed on the Rogers Corporation website at https://www.rogerscorp.com/investors.

About Rogers Corporation

Rogers Corporation (NYSE:ROG) is a global leader in engineered materials to power, protect and connect our world. Rogers delivers innovative solutions to help our customers solve their toughest material challenges. Rogers’ advanced electronic and elastomeric materials are used in applications for EV/HEV, automotive safety and radar systems, mobile devices, renewable energy, wireless infrastructure, energy-efficient motor drives, industrial equipment and more. Headquartered in Chandler, Arizona, Rogers operates manufacturing facilities in the United States (U.S.), Asia and Europe, with sales offices worldwide.

Safe Harbor Statement

Statements included in this release that are not a description of historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are generally accompanied by words or phrases such as “anticipate,” “assume,” “believe,” “could,” “estimate,” “expect,” “foresee,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “seek,” “target” or similar expressions that convey uncertainty as to the future events or outcomes. Forward-looking statements are based on assumptions and beliefs that we believe to be reasonable; however, assumed facts almost always vary from actual results, and the differences between assumed facts and actual results could be material depending upon the circumstances. Where we express an expectation or belief as to future results, that expectation or belief is expressed in good faith and based on assumptions believed to have a reasonable basis. We cannot assure you, however, that the stated expectation or belief will occur or be achieved or accomplished. This release contains forward-looking statements regarding our plans, objectives, outlook, goals, strategies, future events, future net sales or performance, capital expenditures, future restructuring, plans or intentions relating to expansions, business trends and other information that is not historical information. All forward-looking statements are based upon information available to us on the date of this release and are subject to risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to differ materially from those indicated by the forward-looking statements. Other risks and uncertainties that could cause such results to differ include the following, without limitation: failure to capitalize on, volatility within, or other adverse changes with respect to growth opportunities, such as delays in adoption or implementation of new technologies; uncertain business, economic and political conditions in the U.S. and abroad, particularly in China, Germany, England, Belgium, South Korea and Hungary, where we maintain significant manufacturing, sales or administrative operations; the global trade policy dynamics between nations reflected in trade agreement negotiations, imposition of tariffs and other trade restrictions, as well as the potential for global supply chain decoupling; fluctuations in foreign currency exchange rates; our ability to develop innovative products and the extent to which they are incorporated into end-user products and systems that achieve commercial success; the ability and willingness of our sole or limited source suppliers to deliver certain key raw materials, including commodities, to us in a timely and cost-effective manner; business interruptions due to catastrophes or other similar events, such as natural disasters, war, terrorism or public health crises; the impact of sanctions, export controls and other foreign asset or investment restrictions; failure to realize, or delays in the realization of anticipated benefits of acquisitions and divestitures due to, among other things, the existence of unknown liabilities or difficulty integrating acquired businesses; our ability to attract and retain management and skilled technical personnel; our ability to protect our proprietary technology from infringement by third parties and/or allegations that our technology infringes third party rights; changes in effective tax rates or tax laws and regulations in the jurisdictions in which we operate; failure to comply with financial and restrictive covenants in our credit agreement or restrictions on our operational and financial flexibility due to such covenants; the outcome of ongoing and future litigation, including our asbestos-related product liability litigation; changes in environmental laws and regulations applicable to our business; and disruptions in, or breaches of, our information technology systems. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the Company. Our forward-looking statements are expressly qualified by these cautionary statements, which you should consider carefully. For additional information about the risks, uncertainties and other factors that may affect our business, please see our most recent annual report on Form 10-K and any subsequent reports filed with the Securities and Exchange Commission, including quarterly reports on Form 10-Q. Rogers Corporation assumes no responsibility to update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

(Financial statements follow)

Condensed Consolidated Statements of Operations (Unaudited)

(DOLLARS AND SHARES IN MILLIONS, EXCEPT PER SHARE AMOUNTS)

Three Months Ended

March 31, 2026

March 31, 2025

Net sales

$

200.5

$

190.5

Cost of sales

135.9

133.5

Gross margin

64.6

57.0

Selling, general and administrative expenses

41.2

44.5

Research and development expenses

6.7

7.1

Restructuring and impairment charges

5.9

5.9

Other operating (income) expense, net

0.1

(0.2

)

Operating income (loss)

10.7

(0.3

)

Other income (expense), net

0.3

(1.6

)

Interest income, net

0.3

0.3

Income (loss) before income taxes

11.3

(1.6

)

Income tax (benefit) expense

6.8

(0.2

)

Net income (loss)

$

4.5

$

(1.4

)

Basic earnings (loss) per share

$

0.25

$

(0.08

)

Diluted earnings (loss) per share

$

0.25

$

(0.08

)

Shares used in computing:

Basic earnings (loss) per share

17.8

18.5

Diluted earnings (loss) per share

17.9

18.5

Condensed Consolidated Statements of Financial Position (Unaudited)

(DOLLARS AND SHARES IN MILLIONS, EXCEPT PAR VALUE)

March 31, 2026

December 31, 2025

Assets

Current assets

Cash and cash equivalents

$

195.8

$

197.0

Accounts receivable, net

142.1

130.6

Contract assets

25.9

27.9

Inventories, net

127.5

125.0

Asbestos-related insurance recoverables, current portion

4.7

4.7

Other current assets

15.4

14.8

Total current assets

511.4

500.0

Property, plant and equipment, net of accumulated depreciation

363.9

372.4

Operating lease right-of-use assets

18.5

19.2

Goodwill

301.2

303.4

Intangible assets, net of accumulated amortization

95.8

99.3

Asbestos-related insurance recoverables, non-current portion

48.1

48.1

Deferred income taxes

67.8

67.0

Other long-term assets

19.8

20.5

Total assets

$

1,426.5

$

1,429.9

Liabilities and Shareholders’ Equity

Current liabilities

Accounts payable

$

52.8

$

42.9

Accrued employee benefits and compensation

37.1

43.2

Accrued income taxes payable

9.9

10.2

Operating lease obligations, current portion

4.0

3.9

Asbestos-related liabilities, current portion

5.5

5.5

Other accrued liabilities

18.0

20.4

Total current liabilities

127.3

126.1

Operating lease obligations, non-current portion

17.5

17.9

Asbestos-related liabilities, non-current portion

51.8

51.9

Non-current income tax

5.0

4.8

Deferred income taxes

17.5

17.7

Other long-term liabilities

14.7

15.8

Shareholders’ equity

Capital stock - $1 par value; 50.0 authorized shares; 17.8 and 17.8 shares issued and outstanding, respectively

17.8

17.8

Additional paid-in capital

106.1

105.7

Retained earnings

1,123.8

1,119.3

Accumulated other comprehensive loss

(55.0

)

(47.1

)

Total shareholders' equity

1,192.7

1,195.7

Total liabilities and shareholders' equity

$

1,426.5

$

1,429.9

Reconciliation of non-GAAP financial measures to the comparable GAAP measures

Non-GAAP Financial Measures:

This earnings release includes the following financial measures that are not presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”):

(1) Adjusted earnings per diluted share, which the Company defines as earnings (loss) per diluted share excluding acquisition and related integration costs, dispositions, intangible amortization, (gains) losses on the sale or disposal of property, plant and equipment, restructuring, severance, impairment and other related costs, asbestos-related charges (credits), and the related income tax effect on these items, and charges to income tax expense for valuation allowances on deferred tax assets generated in prior years, divided by adjusted weighted average shares outstanding - diluted;

(2) Adjusted EBITDA, which the Company defines as net income (loss) excluding acquisition and related integration costs, dispositions, intangible amortization, (gains) losses on the sale or disposal of property, plant and equipment, restructuring, severance, impairment and other related costs, asbestos-related charges (credits), interest income (expense), net, income tax (benefit) expense , depreciation of fixed assets, and equity compensation expense;

(3) Adjusted EBITDA margin, which the Company defines as the percentage that results from dividing Adjusted EBITDA by total net sales;

(4) Free cash flow, which the Company defines as net cash provided by operating activities less non-acquisition capital expenditures.

Management believes adjusted earnings per diluted share, adjusted EBITDA and adjusted EBITDA margin are useful to investors because they allow for comparison to the Company’s performance in prior periods without the effect of items that, by their nature, tend to obscure the Company’s core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. As a result, management believes that these measures enhance the ability of investors to analyze trends in the Company’s business and evaluate the Company’s performance relative to peer companies. Management also believes free cash flow is useful to investors as an additional way of viewing the Company's liquidity and provides a more complete understanding of factors and trends affecting the Company's cash flows. However, non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as alternatives to, financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from, and should not be compared to, similarly named measures used by other companies. Reconciliations of the differences between these non-GAAP financial measures and their most directly comparable financial measures calculated in accordance with GAAP are set forth below.

The Company provides quarterly guidance for adjusted earnings per diluted share and adjusted EBITDA on a non-GAAP basis only. The forward-looking comparable GAAP measures and a reconciliation of adjusted earnings per share and adjusted EBITDA to GAAP are excluded in reliance upon the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K due to the inherent difficulty in forecasting and quantifying, without unreasonable efforts, certain reconciling items. These include, among other things, adjustments that could be made for acquisition and related integration costs, dispositions, intangible amortization, (gains) losses on the sale or disposal of property, plant and equipment, restructuring, severance, impairment and other related costs, asbestos-related charges (credits), and charges to income tax expense for valuation allowances on deferred tax assets generated in prior years, and other charges reflected in the Company’s reconciliations of historic numbers, the amount of which, based on historical experience, could be significant.

Reconciliation of GAAP Earnings (Loss) Per Diluted Share to Adjusted Earnings Per Diluted Share*:

2026

2025

Q1

Q4

Q1

GAAP Earnings (Loss) Per Diluted Share

$

0.25

$

0.26

$

(0.08

)

Acquisition & Divestiture Related Costs:

Acquisition & Related Integration Costs

—

—

—

Intangible Amortization

0.15

0.16

0.15

(Gain) Loss on Sale or Disposal of PPE

—

—

—

Restructuring, Business Realignment & Other Cost Saving Initiatives:

Restructuring, Severance, Impairment & Other Related Costs

0.33

0.44

0.32

Asbestos-Related Charges (Credits)

—

—

—

Valuation Allowances against Deferred Tax Assets

—

(0.05

)

—

Estimated Income Tax Impacts of Adjustments

0.02

0.09

(0.11

)

Impact of Including Dilutive Securities

—

—

—

Total Adjustments

$

0.50

$

0.64

$

0.35

Adjusted Earnings Per Diluted Share

$

0.75

$

0.89

$

0.27

*Values in table may not add due to rounding.

The following table reconciles weighted average shares outstanding - diluted under US GAAP to adjusted weighted average shares outstanding - diluted used in the calculation of adjusted diluted EPS:

2026

2025

(shares in millions)

Q1

Q4

Q1

Weighed average shares outstanding - diluted

17.9

18.0

18.5

Dilutive effect of awards under equity compensation plans

—

—

—

Adjusted weighted average shares outstanding - diluted

17.9

18.0

18.5

Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA*:

2026

2025

(dollars in millions)

Q1

Q4

Q1

GAAP Net Income (Loss)

$

4.5

$

4.6

$

(1.4

)

Acquisition & Divestiture Related Costs:

Acquisition & Related Integration Costs

—

—

—

Dispositions

—

—

—

Intangible Amortization

2.7

2.8

2.7

(Gain) Loss on Sale or Disposal of PPE

—

—

—

Restructuring, Business Realignment & Other Cost Saving Initiatives:

Restructuring, Severance, Impairment & Other Related Costs

5.9

8.0

5.9

Asbestos-Related Charges (Credits)

—

—

—

Interest (Income) Expense, net

(0.3

)

0.1

(0.3

)

Income Tax (Benefit) Expense

6.8

4.9

(0.2

)

Depreciation

10.7

11.8

9.2

Equity Compensation

1.7

2.2

3.6

Total Adjustments

$

27.5

$

29.8

$

20.9

Adjusted EBITDA

$

32.0

$

34.4

$

19.5

*Values in table may not add due to rounding.

Calculation of Adjusted EBITDA margin*:

2026

2025

(dollars in millions)

Q1

Q4

Q1

Adjusted EBITDA

$

32.0

$

34.4

$

19.5

Divided by Total Net Sales

200.5

201.5

190.5

Adjusted EBITDA Margin

16.0

%

17.1

%

10.2

%

Reconciliation of Net Cash Provided By Operating Activities to Free Cash Flow:

2026

2025

(dollars in millions)

Q1

Q4

Q1

Net Cash Provided By Operating Activities

$

5.8

$

46.9

$

11.7

Non-Acquisition Capital Expenditures

(4.7

)

(4.7

)

(9.6

)

Free Cash Flow

$

1.1

$

42.2

$

2.1

View source version on businesswire.com: https://www.businesswire.com/news/home/20260428126742/en/
Investor Contact:

Steve Haymore

Phone: 480-917-6026

Email: stephen.haymore@rogerscorporation.com
Website Address: https://www.rogerscorp.com

Original: Rogers Corporation Reports First Quarter 2026 Results

New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive toolsMarch 5, 2026 1:15 AM
PR Newswire (US)

Global survey of 4,326 people with diabetes shows how the unpredictability and mental burden associated with managing the condition negatively impacts daily life.1Majority of respondents say that constantly planning around blood glucose levels, meal times, and medication schedules interfere with routine activities from childcare and work, to sport and travelling.1 Eight in ten respondents say that they would value predictive tools that, for example, can predict glucose changes before they occur.1BASEL, Switzerland, March 5, 2026 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today findings from a global survey of 4,326 people with diabetes across 22 countries, exploring the logistical and emotional challenges they face in daily life.1 The survey highlights the unpredictable nature of living with diabetes and the multiple daily decisions that can make it difficult to plan ahead, with the majority (61%) of respondents reporting that they feel less confident that a day will go as planned. This is felt as a significant mental burden by almost two thirds (61%) of people with diabetes, rising to nearly three quarters (71%) for those with Type 1 diabetes.1

The findings are representative of a growing global challenge. Currently over 11% of adults (aged 20-79) live with diabetes, and a further four in ten are unaware they have the condition. This burden is set to increase; by 2050 prevalence is expected to rise by 46%, affecting one in eight adults, approximately 853 million worldwide.5
For those living with diabetes, fluctuations in blood glucose and other events associated with the condition require constant vigilance around activities that might otherwise seem routine. Survey respondents reported that they find a range of activities are negatively impacted by diabetes, from taking part in sports (57%), to taking care of children and household chores (55%), travelling (55%), and even work, with 57% saying the condition affects their ability to take on new professional responsibilities.1 Sleep is another significant challenge, with 55% of respondents reporting that the condition negatively impacts their ability to fall asleep.1 As a result, 59% report that they struggle to feel rested in the morning, and 71% report often feeling tired because of their diabetes.1However, the survey also reveals that there are ways to mitigate the burden of the condition. Eight in ten respondents say that they would value predictive tools that, for example, can predict glucose changes before they occur and 46% said they would feel more in control of their disease in everyday life, if they could see trends before they turn into problems.1 This highlights the need for smarter diabetes management solutions that move beyond reporting current glucose levels to providing insights to help gain flexibility, freedom, and peace of mind. Smarter tools that predict glucose levels could help people with diabetes feel safer, more confident and more in control."This survey brings to light the daily and long-term challenges faced by people with diabetes", said Claire Marriott, Medical Affairs Lead, EMEA-LATAM, Roche Diagnostics. "By better understanding the reality of people living with diabetes, we can work to ease the daily burden of diabetes management, support them in reducing their risk of long-term complications, and help them feel more in control of their lives."Managing diabetes is an around the clock task, requiring constant checking of glucose levels and planning for how upcoming meals or activities may affect them. The survey findings provide a range of insights into just how difficult managing everyday life can be, with 70% of survey respondents feeling anxious about the future, and only one in three feeling very confident in how they currently manage their condition.1Roche will be sharing findings from this survey along with new real-world evidence comparing predictive technology with standard continuous glucose monitoring systems that only provide real-time information, at a medical symposium at the upcoming 19th?International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona on 11 March, 2026.Summary of Key Findings166% of respondents say the condition significantly affects their emotional wellbeing. This figure rises to 77% among those with Type 1 diabetes.61% of respondents say diabetes represents a mental burden. This figure rises to 71% among those with Type 1 diabetes.1Eight in ten respondents say that they would value predictive tools that, for example, can predict glucose changes before they occur.61% of respondents say diabetes negatively impacts their confidence that the day ahead will go as planned. This figure rises to 70% among those with Type 1 diabetes, and 68% of those who have Type 2 diabetes treated with insulin.Only one in three respondents feel very confident in how they currently manage their diabetes.71% of respondents say they are often feeling tired because of their diabetes, with 55% saying it negatively impacts their ability to fall asleep.54% of respondents report that diabetes negatively impacts their ability to be spontaneous with last-minute social invitations and 51% their ability to manage unexpected events like being stuck in traffic or in meetings that run over.1About Diabetes
Diabetes is a chronic condition that occurs either when the pancreas does not produce enough insulin, a hormone that regulates blood glucose levels, or when the body can't effectively use the insulin it produces.2Type 1 diabetes is an autoimmune condition preventing the pancreas from producing insulin.3 Type 2 diabetes occurs when the pancreas doesn't produce enough insulin and/or when the body's cells don't use insulin efficiently, also known as insulin resistance.4 Although these are the most common types of diabetes, the condition can come in several forms. Other types of diabetes include gestational diabetes, neonatal, type 3c diabetes that's caused by a dysfunction or removal of the pancreas, steroid-induced diabetes and latent autoimmune diabetes in adults (LADA).4Over 11% of the adult population aged 20-79 years is reported to be living with diabetes, with an estimated four in ten unaware that they have the condition.5 And the burden is increasing. Projections show that in 2050, one in eight adults globally, approximately 853 million, will be living with diabetes, an increase of 46%.5
Diabetes generally can't be cured, so it's essential to help people keep their blood glucose values in range, meaning in a zone where the blood glucose values are neither too high (hyperglycaemia) nor too low (hypoglycaemia). This is easier said than done, because a multitude of factors can influence blood glucose, including: physical activity, sleep, stress, extreme temperatures and much more.6 Technology such as continuous glucose monitoring devices is helping people with diabetes better control glucose levels and manage life with the condition.About the Survey
This research is based on data from a GWI research study commissioned by Roche in September 2025, exploring diabetes perceptions, life with diabetes, and management tools. The study surveyed 4,326 people with diabetes (PwD) aged 16+ globally, as part of a wider study among 16,310 internet users across 22 countries. Markets include Australia, Austria, Belgium, Brazil, Chile, Croatia, Czech Republic, Denmark, Germany, Hong Kong, India, Japan, Kuwait, Netherlands, Poland, Portugal, Romania, Saudi Arabia, South Africa, Spain, Turkey, and the UK.About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.For more information, please visit www.roche.com.All trademarks used or mentioned in this release are protected by law.References
[1] GWI – Roche. Diabetes Survey 2025.
[2] International Diabetes Federation, About Diabetes. Available at URL: https://idf.org/about-diabetes/what-is-diabetes/ [Accessed January 2026].
[3] Centers for Disease Control, About Type 1 Diabetes. Available at URL:
https://www.cdc.gov/diabetes/about/about-type-1-diabetes.html [Accessed January 2026].
[4] Diabetes UK, Types of Diabetes. Available at URL: https://www.diabetes.org.uk/about-diabetes/types-of-diabetes [Accessed January 2026].
[5] International Diabetes Federation, Facts and Figures. Available at URL: https://idf.org/about-diabetes/diabetes-facts-figures/ [Accessed January 2026].
[6] DiaTribe. 42 Factors that Affect Blood Glucose. Available at URL: https://diatribe.org/sites/default/files/42FactorsPDF%20-%20October%2028%2C%202018.pdf [Accessed January 2026].For further information please contactRoche Diagnostics CommunicationsKathryn Ager
Senior Communications Business Partner, Roche Diagnostics
kathryn.ager@roche.com
Phone: +44 07745 115046

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-survey-demonstrates-how-diabetes-limits-day-to-day-freedom-for-people-around-the-world-and-highlights-need-for-predictive-tools-302704236.htmlSOURCE F. Hoffman-La Roche AG

Original: New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools